0001615774-17-005170.txt : 20170918
0001615774-17-005170.hdr.sgml : 20170918
20170918211319
ACCESSION NUMBER: 0001615774-17-005170
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170918
FILED AS OF DATE: 20170918
DATE AS OF CHANGE: 20170918
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vivo Capital VIII, LLC
CENTRAL INDEX KEY: 0001618789
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37558
FILM NUMBER: 171091005
BUSINESS ADDRESS:
STREET 1: 505 HAMILTON AVENUE, SUITE 200
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: 650 688 0822
MAIL ADDRESS:
STREET 1: 505 HAMILTON AVENUE, SUITE 200
CITY: PALO ALTO
STATE: CA
ZIP: 94301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nabriva Therapeutics plc
CENTRAL INDEX KEY: 0001641640
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 56 FITZWILLIAM SQUARE
CITY: DUBLIN
STATE: L2
ZIP: 2
BUSINESS PHONE: (610) 816-6640
MAIL ADDRESS:
STREET 1: 1000 CONTINENTAL DRIVE
STREET 2: SUITE 600
CITY: KING OF PRUSSIA
STATE: PA
ZIP: 19406
FORMER COMPANY:
FORMER CONFORMED NAME: Nabriva Therapeutics AG
DATE OF NAME CHANGE: 20150507
4
1
s107542_f4.xml
OWNERSHIP DOCUMENT
X0306
4
2017-09-18
0
0001641640
Nabriva Therapeutics plc
NBRV
0001618789
Vivo Capital VIII, LLC
505 HAMILTON AVENUE, SUITE 207
PALO ALTO
CA
94301
0
0
1
0
Common Stock
2017-09-18
4
P
0
46245
9.46
A
3579861
I
by Vivo Hong Kong VIII, Co., Limited
Common Stock
2017-09-18
4
P
0
6386
9.46
A
494329
I
Vivo Hong Kong Surplus VIII, Co., Limited
These shares are owned directly by Vivo Hong Kong VIII, Co., Limited and Vivo Hong Kong Surplus VIII, Co., Limited, which are the record owners (together, the "Record Owners") of these shares. The Record Owners are wholly owned subsidiaries of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., respectively (together, the "Parents").
Vivo Capital VIII, LLC is the general partner of the Parents and disclaims beneficial ownership over these shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. The voting members of Vivo Capital VIII, LLC are Dr. Frank Kung, Dr. Albert Cha, Dr. Edgar Engleman, Dr. Chen Yu, and Mr. Shan Fu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.33 to $9.60, inclusive. The reporting person undertakes to provide to Nabriva Therapeutics plc, any security holder of Nabriva Therapeutics plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
/s/ Albert Cha, Managing Member
2017-09-18